---
title: Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs
  Recognize Ebolavirus Glycoprotein
type: pub
encoding: UTF-8

---
<h1>Publication</h1>
<article id="csl-bib-container-EQT7XYW7" class="csl-bib-container">
  <div class="csl-bib-body"> <div class="csl-entry">Jarahian, M., Marstaller, K., Banna, N., Ahani, R., Etemadzadeh, M. H., Boller, L. K., Azadmanesh, K., Cid-Arregui, A., Khezri, A., Berger, M. R., Momburg, F., &#38; Watzl, C. (2021). Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein. <i>Journal of Innate Immunity</i>. <a href="https://doi.org/10.1159/000517628">https://doi.org/10.1159/000517628</a></div> </div>
  <div class="csl-bib-buttons">
    <a href="#taxonomy-article-EQT7XYW7" alt="archive" class="csl-bib-button">Archive</a>
    <a href="https://app.cristin.no/results/show.jsf?id=1965731" alt="Cristin" class="csl-bib-button">Cristin</a>
    <a href="http://zotero.org/groups/5881554/items/EQT7XYW7" alt="Zotero" class="csl-bib-button">Zotero</a>
    <a href="#keywords-article-EQT7XYW7" alt="keywords" class="csl-bib-button">Keywords</a>
    <a href="#about-article-EQT7XYW7" alt="about_pub" class="csl-bib-button">About</a>
    <a href="#sdg-article-EQT7XYW7" alt="sdg" class="csl-bib-button">Sustainable Development Goals</a>
    <a href="https://www.karger.com/Article/Pdf/517628" alt="Unpaywall" class="csl-bib-button">Unpaywall</a>
    <a href="https://www.karger.com/Article/Pdf/517628" alt="EZproxy" class="csl-bib-button">EZproxy</a>
  </div>
  <div id="csl-bib-meta-container-EQT7XYW7"></div>
</article>
<div id="csl-bib-meta-EQT7XYW7" class="csl-bib-meta">
  <article id="about-article-EQT7XYW7" class="about_pub-article">
    <h1>About</h1>
    Jarahian et al. studied how the glycoprotein of the Ebolavirus (EBOV-GP) interacts with various receptors on human cells. They found that EBOV-GP can bind to natural killer (NK) cell receptors, selectins (molecules that help cells stick together), and inhibitory receptors like Siglecs. These interactions can both activate and suppress the immune system, making it harder for NK cells to destroy infected cells. This dual effect shows the complex battle between the immune system and viruses. Understanding these interactions could lead to new ways to treat Ebola infections by targeting these specific receptors and improving immune responses. This research is published in the Journal of Innate Immunity.
  </article>
  <article id="keywords-article-EQT7XYW7" class="keywords-article">
    <h1>Keywords</h1>
    Ebolavirus Glycoprotein, Natural Killer Cells, Selectins, Siglecs, Immune System, Viral Pathogenicity
  </article>
  <article id="abstract-article-EQT7XYW7" class="abstract-article">
    <h1>Scientific abstract</h1>
    Expression of the extensively glycosylated Ebolavirus glycoprotein (EBOV-GP) induces physical alterations of surface molecules and plays a crucial role in viral pathogenicity. Here we investigate the interactions of EBOV-GP with host surface molecules using purified EBOV-GP, EBOV-GP-transfected cell lines, and EBOV-GP-pseudotyped lentiviral particles. Subsequently, we wanted to examine which receptors are involved in this recognition by binding studies to cells transfected with the EBOV-GP as well as to recombinant soluble EBOVGP. As the viral components can also bind to inhibitory receptors of immune cells (e.g., Siglecs, TIM-1), they can even suppress the activity of immune effector cells. Our data show that natural killer (NK) cell receptors NKp44 and NKp46, selectins (CD62E/P/L), the host factors DC-SIGNR/DC-SIGN, and inhibitory Siglecs function as receptors for EBOV-GP. Our results show also moderate to strong avidity of homing receptors (P-, L-, and E-selectin) and DC-SIGNR/DC-SIGN to purified EBOV-GP, to cells transfected with EBOV-GP, as well as to the envelope of a pseudotyped lentiviral vector carrying the EBOV-GP. The concomitant activation and inhibition of the immune system exemplifies the evolutionary antagonism between the immune system and pathogens. Altogether these interactions with activating and inhibitory receptors result in a reduced NK cell-mediated lysis of EBOVGP- expressing cells. Modulation of these interactions may provide new strategies for treating infections caused by this virus.
  </article>
  <article id="sdg-article-EQT7XYW7" class="sdg-article">
    <h1>Sustainable Development Goals</h1>
    <div class="sdg-container"><div id="sdg3" class="sdg">
        <img src="{{< params subfolder >}}images/sdg/sdg03_en.png" class="image" alt="SDG 3">
        <div class="sdg-overlay">
          <a href="{{< params subfolder >}}en/archive/?sdg=3#archive" class="sdg-publication-count"><span>1358</span> publications</a>
          <p><a href="https://sdgs.un.org/goals/goal3" class="sdg-read-more">Read More</a></p>
        </div>
      </div></div>
  </article>
  <article id="taxonomy-article-EQT7XYW7" class="taxonomy-article">
    <h1>Archive</h1>
    <ul>
      <li><a href="{{< params subfolder >}}en/archive/?key=3DCRN523">University of Inland Norway</a></li>
      <li><a href="{{< params subfolder >}}en/archive/?key=T77LXH6D">Faculty of Applied Ecology, Agricultural Sciences and Biotechnology</a></li>
      <li><a href="{{< params subfolder >}}en/archive/?key=VL6KDQ85">Department of Biotechnology</a></li>
      <li><a href="{{< params subfolder >}}en/archive/?key=FJH75VJD">2021</a></li>
      <li><a href="{{< params subfolder >}}en/archive/?key=H75X8VE3">December</a></li>
    </ul>
  </article>
</div>
